Compare BRT & CABA Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
| Metric | BRT | CABA |
|---|---|---|
| Founded | 1972 | 2017 |
| Country | United States | United States |
| Employees | N/A | N/A |
| Industry | Real Estate Investment Trusts | Biotechnology: Biological Products (No Diagnostic Substances) |
| Sector | Real Estate | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 269.9M | 319.6M |
| IPO Year | 1994 | 2019 |
| Metric | BRT | CABA |
|---|---|---|
| Price | $14.23 | $2.93 |
| Analyst Decision | Strong Buy | Strong Buy |
| Analyst Count | 2 | 6 |
| Target Price | ★ $19.75 | $14.50 |
| AVG Volume (30 Days) | 65.4K | ★ 1.9M |
| Earning Date | 05-08-2026 | 05-14-2026 |
| Dividend Yield | ★ 7.04% | N/A |
| EPS Growth | N/A | ★ 10.26 |
| EPS | ★ N/A | N/A |
| Revenue | ★ $97,028,000.00 | N/A |
| Revenue This Year | $3.82 | N/A |
| Revenue Next Year | $5.35 | N/A |
| P/E Ratio | ★ N/A | N/A |
| Revenue Growth | ★ 1.46 | N/A |
| 52 Week Low | $13.18 | $1.11 |
| 52 Week High | $16.69 | $3.78 |
| Indicator | BRT | CABA |
|---|---|---|
| Relative Strength Index (RSI) | 53.12 | 44.25 |
| Support Level | $13.18 | $2.32 |
| Resistance Level | $15.02 | $3.34 |
| Average True Range (ATR) | 0.29 | 0.20 |
| MACD | 0.04 | -0.02 |
| Stochastic Oscillator | 57.26 | 5.89 |
BRT Apartments Corp is a real estate investment trust company. The company is focused on the ownership, operation, and development of multi-family properties. BRT also owns and operates other real estate assets. All of the Company's assets are comprised of multi-family real estate assets generally leased to tenants on a one-year basis.
Cabaletta Bio Inc is a clinical-stage biotechnology company focused on the discovery and development of engineered T cell therapies and exploring their potential to provide a deep and durable, perhaps curative, treatment for patients with B cell-mediated autoimmune diseases. Its proprietary technology utilizes Chimeric AutoAntibody Receptor, or CAART cells, that are designed to selectively bind and eliminate only specific B cells that produce disease-causing autoantibodies, or pathogenic B cells, while sparing normal B cells. Its CABA platform encompasses two strategies: CARTA (chimeric antigen receptor T cells for autoimmunity) and CAART (chimeric autoantibody T cells) that have the potential to be applied across a broad range of autoimmune diseases.